fda approves first oral glp-1 obesity drug august 14 2025 Foundayo (orforglipron) – Non-Peptide RA FDA-approved April 2026 for chronic weight management. Once-daily tablet with no fasting requirement, stepwise dosing up to 17.2 mg, and meaningful weight reduction in Beyond GLP-1: the next wave

Digestion of dietary cholesterol esters results via the action of carboxyl ester lipase (CEL)

Legal Disclaimer For external use only

NADPH oxidase exerts a B cell-intrinsic contribution to lupus risk by modulating endosomal TLR signals

An analysis of a community-driven reconstruction of the human metabolic network

We will look at what the company gets right, where questions remain, and what you should verify before placing an order

Response: We understand commenters' concern regarding the timing around removal of these measures and the confusion and burden this may impose on hospitals and ASCs that have already submitted CY 2024 quality data